INAB Key Statistics, Chart & Performance
The current stock price of INAB is 2.05 USD. In the past month the price decreased by -7.17%. In the past year, price decreased by -73.03%.
INAB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to INAB. When comparing the yearly performance of all stocks, INAB is a bad performer in the overall market: 90.94% of all stocks are doing better.
INAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INAB. INAB has a bad profitability rating. Also its financial health evaluation is rather negative.
INAB Financial Highlights
Over the last trailing twelve months INAB reported a non-GAAP Earnings per Share(EPS) of -5.39. The EPS increased by 76.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -123.2% | ||
| ROE | -156.63% | ||
| Debt/Equity | 0 |
INAB Forecast & Estimates
9 analysts have analysed INAB and the average price target is 50.24 USD. This implies a price increase of 2350.49% is expected in the next year compared to the current price of 2.05.
INAB Ownership
About INAB
Company Profile
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Company Info
IN8BIO INC
Empire State Building, 350 5Th Avenue, Suite 5330
New York City NEW YORK US
CEO: William Ho
Employees: 18
Phone: 16466006438
IN8BIO INC / INAB FAQ
What does IN8BIO INC do?
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Can you provide the latest stock price for IN8BIO INC?
The current stock price of INAB is 2.05 USD. The price decreased by -0.97% in the last trading session.
Does INAB stock pay dividends?
INAB does not pay a dividend.
What is the ChartMill rating of IN8BIO INC stock?
INAB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is IN8BIO INC (INAB) stock traded?
INAB stock is listed on the Nasdaq exchange.
Who owns IN8BIO INC?
You can find the ownership structure of IN8BIO INC (INAB) on the Ownership tab.